Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Development and Prospective Validation of a Machine Learning-Based Risk of Readmission Model in a Large Military Hospital
20
Zitationen
14
Autoren
2019
Jahr
Abstract
BACKGROUND: Thirty-day hospital readmissions are a quality metric for health care systems. Predictive models aim to identify patients likely to readmit to more effectively target preventive strategies. Many risk of readmission models have been developed on retrospective data, but prospective validation of readmission models is rare. To the best of our knowledge, none of these developed models have been evaluated or prospectively validated in a military hospital. OBJECTIVES: The objectives of this study are to demonstrate the development and prospective validation of machine learning (ML) risk of readmission models to be utilized by clinical staff at a military medical facility and demonstrate the collaboration between the U.S. Department of Defense's integrated health care system and a private company. METHODS: We evaluated multiple ML algorithms to develop a predictive model for 30-day readmissions using data from a retrospective cohort of all-cause inpatient readmissions at Madigan Army Medical Center (MAMC). This predictive model was then validated on prospective MAMC patient data. Precision, recall, accuracy, and the area under the receiver operating characteristic curve (AUC) were used to evaluate model performance. The model was revised, retrained, and rescored on additional retrospective MAMC data after the prospective model's initial performance was evaluated. RESULTS: Within the initial retrospective cohort, which included 32,659 patient encounters, the model achieved an AUC of 0.68. During prospective scoring, 1,574 patients were scored, of whom 152 were readmitted within 30 days of discharge, with an all-cause readmission rate of 9.7%. The AUC of the prospective predictive model was 0.64. The model achieved an AUC of 0.76 after revision and addition of further retrospective data. CONCLUSION: This work reflects significant collaborative efforts required to operationalize ML models in a complex clinical environment such as that seen in an integrated health care system and the importance of prospective model validation.
Ähnliche Arbeiten
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
2021 · 19.544 Zit.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2021 · 12.680 Zit.
2013 ACCF/AHA Guideline for the Management of Heart Failure
2013 · 12.619 Zit.
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 · 11.735 Zit.
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
2002 · 11.655 Zit.